Cargando…
The drug interaction potential of daprodustat when coadministered with pioglitazone, rosuvastatin, or trimethoprim in healthy subjects
This study was conducted to evaluate the likelihood of daprodustat to act as a perpetrator in drug–drug interactions (DDI) with the CYP2C8 enzyme and OATP1B1 transporter using the probe substrates pioglitazone and rosuvastatin as potential victims, respectively. Additionally, this study assessed the...
Autores principales: | Caltabiano, Stephen, Mahar, Kelly M., Lister, Karyn, Tenero, David, Ravindranath, Ramiya, Cizman, Borut, Cobitz, Alexander R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5843756/ https://www.ncbi.nlm.nih.gov/pubmed/29545948 http://dx.doi.org/10.1002/prp2.327 |
Ejemplares similares
-
Effect of renal function and dialysis modality on daprodustat and predominant metabolite exposure
por: Caltabiano, Stephen, et al.
Publicado: (2019) -
An Exploratory Study of Daprodustat in Erythropoietin-Hyporesponsive Subjects
por: Cizman, Borut, et al.
Publicado: (2018) -
Pharmacokinetics of Daprodustat and Metabolites in Individuals with Normal and Impaired Hepatic Function
por: Mahar, Kelly M., et al.
Publicado: (2022) -
A randomized, 29-day, dose-ranging, efficacy and safety study of daprodustat, administered three times weekly in patients with anemia on hemodialysis
por: Bailey, Christine K., et al.
Publicado: (2019) -
Daprodustat for anemia: a 24-week, open-label, randomized controlled trial in participants on hemodialysis
por: Meadowcroft, Amy M, et al.
Publicado: (2018)